

CRITERIA FOR PRIOR AUTHORIZATION

Kevzara® (sarilumab)

PROVIDER GROUP Pharmacy
Professional

MANUAL GUIDELINES The following drug requires prior authorization:
Sarilumab (Kevzara®)

CRITERIA FOR RHEUMATOID ARTHRITIS (RA): (must meet all of the following)

- Patient must have a diagnosis of rheumatoid arthritis (RA)
- Patient must have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs) (see attached table)
- Must be prescribed by a rheumatologist
- Evaluation for latent tuberculosis (TB) with TB skin test prior to initial prior authorization approval
- Patient must be 18 years of age or older
- Patient has not taken another biologic agent (see attached table) in the past 30 days
- Patient must not have any of the following:
 - ANC less than 2000/mm³
 - Platelets less than 150,000/mm³
 - Liver transaminases above 1.5 times ULN, active hepatic disease, or hepatic impairment (including patients with positive HBV or HCV serology)

LENGTH OF APPROVAL 12 months

Notes:

- The recommended dosage is 200 mg once every two weeks, administered as a subcutaneous injection.

DRUG UTILIZATION REVIEW COMMITTEE CHAIR

PHARMACY PROGRAM MANAGER
DIVISION OF HEALTH CARE FINANCE
KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT

DATE

DATE

Biologic Agents	
Generic Name	Brand Name
Abatacept	Orencia®
Adalimumab	Humira®, Amjevita®
Alefacept	Amevive®
Anakinra	Kineret®
Certolizumab	Cimzia®
Golimumab	Simponi®
Tocilizumab	Actemra®
Natalizumab	Tysabri®
Rituximab	Rituxan®
Etanercept	Enbrel®, Erelzi®
Tofacitinib	Xeljanz®, Xeljanz XR®
Ustekinumab	Stelara®
Secukinumab	Cosentyx®
Vedolizumab	Entyvio®
Canakinumab	Ilaris®
Apremilast	Otezla®
Ixekizumab	Taltz®
Infliximab	Remicade®, Inflectra®, Renflexis®

Disease-Modifying Antirheumatic Drugs (DMARDs)	
Generic Name	Brand Name
Leflunomide	Arava®
Hydroxychloroquine	Plaquenil®
Methotrexate	Trexall®, Rheumatrex®, Xatmep®, Rasuvo®, Otrexup®
Sulfasalazine	Azulfidine®
Cyclosporine	Sandimmune®
Azathioprine	Imuran®, Azasan®